U.S. markets closed
  • S&P 500

    3,577.59
    +20.05 (+0.56%)
     
  • Dow 30

    29,591.27
    +327.79 (+1.12%)
     
  • Nasdaq

    11,880.63
    +25.66 (+0.22%)
     
  • Russell 2000

    1,818.30
    +32.96 (+1.85%)
     
  • Crude Oil

    42.84
    +0.42 (+0.99%)
     
  • Gold

    1,835.20
    -37.20 (-1.99%)
     
  • Silver

    23.61
    -0.75 (-3.09%)
     
  • EUR/USD

    1.1841
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • GBP/USD

    1.3322
    +0.0031 (+0.23%)
     
  • USD/JPY

    104.4770
    +0.6490 (+0.63%)
     
  • BTC-USD

    18,360.28
    -94.47 (-0.51%)
     
  • CMC Crypto 200

    364.55
    +3.12 (+0.86%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

GRAPHIC-Tracking the vaccine race

·1 min read

Nov 9 (Reuters) - The race to create vaccines against the novel coronavirus is entering a critical stretch, with several candidates that were first out of the gate beginning to release late-stage trial data.

Pfizer Inc and its partner BioNTech SE said on Monday their experimental COVID-19 vaccine is more than 90% effective based on initial trial results, a much higher efficacy rate than the 50% minimum required by the U.S. Food and Drug Administration.

Multiple vaccines are likely to make it to market and success will depend on a number of factors, including immune response, safety and distribution.

Reuters is tracking the candidates closest to producing results in this tracker: https://tmsnrt.rs/36jDuuj (Reporting by Christine Soares, Editing by Tiffany Wu)